Literature DB >> 14963146

Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.

Susan L Payne1, Xiao-fang Pei, Bin Jia, Angela Fagerness, Frederick J Fuller.   

Abstract

The molecular clones pSPeiav19 and p19/wenv17 of equine infectious anemia virus (EIAV) differ in env and long terminal repeats (LTRs) and produce viruses (EIAV(19) and EIAV(17), respectively) of dramatically different virulence phenotypes. These constructs were used to generate a series of chimeric clones to test the individual contributions of LTR, surface (SU), and transmembrane (TM)/Rev regions to the disease potential of the highly virulent EIAV(17). The LTRs of EIAV(19) and EIAV(17) differ by 16 nucleotides in the transcriptional enhancer region. The two viruses differ by 30 amino acids in SU, by 17 amino acids in TM, and by 8 amino acids in Rev. Results from in vivo infections with chimeric clones indicate that both LTR and env of EIAV(17) are required for the development of severe acute disease. In the context of the EIAV(17) LTR, SU appears to have a greater impact on virulence than does TM. EIAV(17SU), containing only the TM/Rev region from the avirulent parent, induced acute disease in two animals, while a similar infectious dose of EIAV(17TM) (which derives SU from the avirulent parent) did not. Neither EIAV(17SU) nor EIAV(17TM) produced lethal disease when administered at infectious doses that were 6- to 30-fold higher than a lethal dose of the parental EIAV(17). All chimeric clones replicated in primary equine monocyte-derived macrophages, and there was no apparent correlation between macrophage tropism and virulence phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963146      PMCID: PMC369206          DOI: 10.1128/jvi.78.5.2478-2485.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.

Authors:  M Belshan; P Baccam; J L Oaks; B A Sponseller; S C Murphy; J Cornette; S Carpenter
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Effects of long terminal repeat sequence variation on equine infectious anemia virus replication in vitro and in vivo.

Authors:  D L Lichtenstein; J K Craigo; C Leroux; K E Rushlow; R F Cook; S J Cook; C J Issel; R C Montelaro
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

5.  Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.

Authors:  C Leroux; J K Craigo; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.

Authors:  Lisa A Chakrabarti; Tijana Ivanovic; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells.

Authors:  J A LaBonte; T Patel; W Hofmann; J Sodroski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.

Authors:  B Etemad-Moghadam; Y Sun; E K Nicholson; M Fernandes; K Liou; R Gomila; J Lee; J Sodroski
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Agnès-Laurence Chenine; Pei-Lin Li; Timothy W Baba; David C Montefiori; Harold M McClure; Daniel C Anderson; Ruth M Ruprecht
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

10.  Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.

Authors:  Z Si; M Cayabyab; J Sodroski
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

View more
  10 in total

1.  Genetic variation in the long terminal repeat associated with the transition of Chinese equine infectious anemia virus from virulence to avirulence.

Authors:  Lili Wei; Xiujuan Fan; Xiaoling Lu; Liping Zhao; Wenhua Xiang; Xiaoyan Zhang; Fei Xue; Yiming Shao; Rongxian Shen; Xiaojun Wang
Journal:  Virus Genes       Date:  2009-01-07       Impact factor: 2.332

2.  The comparison of genetic variation in the envelope protein between various immunodeficiency viruses and equine infectious anemia virus.

Authors:  Qing Yuan; Chang Liu; Zhipin Liang; Xueqing Chen; Danhong Diao; Xiaohong Kong
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

3.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus.

Authors:  Baoshan Zhang; Sha Jin; Jing Jin; Feng Li; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-28       Impact factor: 11.205

5.  EIAV S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages.

Authors:  Lina Covaleda; Frederick J Fuller; Susan L Payne
Journal:  Virology       Date:  2009-11-28       Impact factor: 3.616

6.  Horses naturally infected with EIAV harbor 2 distinct SU populations but are monophyletic with respect to IN.

Authors:  Diana T Cervantes; Judith M Ball; John Edwards; Susan Payne
Journal:  Virus Genes       Date:  2016-01-06       Impact factor: 2.332

7.  Equine infectious anemia virus entry occurs through clathrin-mediated endocytosis.

Authors:  Melinda A Brindley; Wendy Maury
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

8.  Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Authors:  Lianxing Liu; Yanmin Wan; Lan Wu; Jianping Sun; Huiguang Li; Haishan Li; Liying Ma; Yiming Shao
Journal:  Retrovirology       Date:  2010-09-01       Impact factor: 4.602

Review 9.  Equine infectious anemia virus in China.

Authors:  Hua-Nan Wang; Dan Rao; Xian-Qiu Fu; Ming-Ming Hu; Jian-Guo Dong
Journal:  Oncotarget       Date:  2017-08-21

10.  Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo.

Authors:  Xue-Feng Wang; Qiang Liu; Yu-Hong Wang; Shuai Wang; Jie Chen; Yue-Zhi Lin; Jian Ma; Jian-Hua Zhou; Xiaojun Wang
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.